leisure time -WSS

leisure time

author：Wikipedia 2025-09-30 00:46:58 - browse：238

Kevin Sayer, CEO of Dexcom Dexcom

For years, diabetes tech company Dexcom has been striving to get its continuous glucose monitors into the hands of type 2 diabetes patients. Last week at the American Diabetes Association’s conference, the company unveiled plans for software built entirely for these patients, including ones who don’t take insulin.

“We’ve been so focused on things that match the needs of somebody who manages diabetes every minute of every day, and insulin delivery,” Kevin Sayer, CEO of Dexcom, told STAT. “This new product is going to be designed to address the needs of somebody with diabetes who’s not doing that, who has type 2 diabetes and is on other drugs.”

Continuous glucose monitoring is already well-established among people with type 1 diabetes, who rely on constant insulin therapy. The technology, which helps patients noninvasively monitor their blood sugar levels and control their insulin pump in real time, has grown rapidly in use over the years, culminating in a $5 billion market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： 5 dead in mass shooting on Caribbean island of St. Vincent: Police

WSS

Diverse clinical trials: Why aren’t we there yet?

Scientists grapple with ethics of stem cell research

How housing is health care on Long Island

How medical schools plan to diversify without affirmative action

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

Regeneron agrees to White House price limits on anti

Wikipedia

leisure time

focus

BioMarin wins approval for gene therapy to treat hemophilia A

IRA could hurt research into orphan drugs for rare diseases

Wildfire smoke exposes gaps in outdoor worker protections

5 dead in mass shooting on Caribbean island of St. Vincent: Police

Walensky prepares to leave CDC — and Congress — behind

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Sports medicine is finally prioritizing gender equality

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

The high cost of giving birth even with insurance

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

knowledge

In rare move, senator releases unverified FBI source report alleging Biden bribe

Pig kidney works a record two months in donated body

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

5 dead in mass shooting on Caribbean island of St. Vincent: Police

Hospitals consider fixing cancer drug shortages on their own

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

hotspot

hotspot

entertainment

explore